Partner Organizations and Blogs
Medical Letter: first published in 1959, this biweekly newsletter provides independent, unbiased critical appraisals of new drugs and comparative reviews of older drugs.
Healthy Skepticism: an International organization whose main aim is “to improve health by reducing harm from misleading drug promotion.” In addition to helpful resources, they have an extensive, up-to-date library with references relative to drug promotion.
The Unbranded Doctor: A National Physicians Alliance's campaign created to unmask the Pharmaceutical Industry's bogus claim that its marketing efforts are just educational ventures for physicians. The National Physicians Alliance, founded in 2005 by former leaders of the American Medical Student Association, seeks to restore physicians' primary emphasis on the core values of our profession: service, integrity, and advocacy.
The Prescription Project: Funded by the Pew Charitable Trusts, the Project seeks to eliminate conflicts of interest created by industry marketing by promoting policy change among academic medical centers, professional medical societies and public and private payers.
De-Fib: A site run by University of Rochester Medical Students with the goal of "Demanding Evidence, Forgoing Industry Bias."
Médecins Sans Frontières (MSF or Doctors Without Borders) Access to Medicines Campaign: International group that was one of the initial driving forces behind the Yale d4T protests, and continues to work for improved access by "conducting price analyses, identifying high-quality, low-cost drug sources, supporting health ministries, and working with the WHO in addition to its large humanitarian aid projects." MSF also issues influential statements on issues of access to medicines.
Universities Allied for Essential Medicines (UAEM): Group of US and Canadian students in professional, graduate, and undergraduate schools. Work to (1) determine how universities can help ensure that biomedical end products, such as drugs, are made more accessible in poor countries and (2) increase the amount of research conducted on neglected diseases, or those diseases predominantly affecting people who are too poor to constitute a market attractive to private-sector R&D investment.